BCL2L1 and hepatocellular carcinoma: Therefore, ABT-737 or the orally available version ABT-263 might be more effective in BCL-XL-expressing tumors, e.g., HCC, compared to ABT-199, which more specifically inhibits BCL-2 [22–26].